Decoding 10 Analyst Evaluations For CG Oncology
Decoding 10 Analyst Evaluations For CG Oncology
解码 CG 肿瘤学的 10 项分析师评估
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.
在最近一个季度中，10位分析师为CG Oncology（纳斯达克股票代码：CGON）提供了评级，显示了看涨和看跌的观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要概述了他们最近的评级，重点介绍了过去30天中情绪的变化，并将其与前几个月进行了比较。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.7, with a high estimate of $75.00 and a low estimate of $42.00. Marking an increase of 50.47%, the current average surpasses the previous average price target of $43.00.
分析师对12个月目标股价的评估提供了更多见解，显示平均目标股价为64.7美元，最高估计为75.00美元，低估值为42.00美元。目前的平均价格上涨了50.47％，超过了之前的平均目标股价43.00美元。
Exploring Analyst Ratings: An In-Depth Overview
探索分析师评级：深入概述
A comprehensive examination of how financial experts perceive CG...
对金融专家如何看待...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。